Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Does the FDA approval of aducanumab mark the return of science-based medicine?

Robert Trent
Meds
July 4, 2021
1 Shares
Share
Tweet
Share

The 20th century was an explosion of scientific innovation and discovery. The success of chemistry, physics and biology to produce things such as antibiotics, radiography and genetic analysis could not be ignored.

Medicine is not now, nor has it ever been, a “science.” But over the past century, medicine became science-based. This means that while medicine was not in adherence with the scientific method, it did rely on underlying scientific principles, conceptual frameworks, and methodologies.

As scientific innovation began to stagnate, social activism and political advocacy began to grow significantly. This caused medicine to adopt a different set of value systems, most of which came from the social sciences. This resulted in the modern system of medicine we see today ( i.e., evidence-based medicine).

David Gorski over at Science-Based Medicine frequently discusses the issues that have arisen from this development: “As currently practiced, EBM (evidence-based medicine) appears to worship clinical trial evidence above all else and nearly completely ignores basic science considerations, relegating them to the lowest form of evidence, lower than even small case series. This blind spot has directly contributed to the infiltration of quackery into academic medicine.”

The adoption of evidence-based medicine resulted in a multitude of changes in the underlying conceptual frameworks that medicine uses to make decisions. One example would be utilizing treatment based on statistical and clinical outcomes with zero regard for biochemical roles and functions.

Theoretical biologist Stuart Kauffman (along with the virologist Nessa Carey) pointed out that if you just look at the statistical relationships among components in medicine, it will lead you down a blind alley. You will conclude that the heart exists solely to add weight to the chest: filling up space between the lungs.

I stress this point because statistics is not a science. Statistics can tell you if your data are significant or not, but they cannot say anything about your methodology and experimental design. I mention this because many brilliant clinicians are never given formal education in raw statistics and do not understand probability.

Regardless, many physicians make clinical decisions based solely on “statistics” and “probability” with zero regard for the underlying mechanistic relationships between the variables that they are operating on.

To put it in Kaufman’s terms, they make clinical decisions based on the idea that the heart exists to add weight to the chest and not to pump blood.

To give one example of many: Several well-respected physicians do not believe that proton pump inhibitors (PPIs) increase the risk of contracting the superbug: Clostridium difficile (C. Diff). They reason that “the probability is low,” completely ignoring the fact that the C.Diff grows at an optimum pH of 6, which is within the pH range of stomach acid for patients taking PPIs.

It would seem that this pathological “clinical data above everything else” way of thinking, which permeates almost every aspect of our health care system, has finally begun to reverse course — at least with regards to how the FDA operates.

This is most exemplified by the recent approval of aducanumab for Alzheimer’s patients. As STAT News’ Adam Feuerstein and Damian Garde reported: “Instead of judging Biogen’s treatment solely on its effects on cognition, the FDA granted a conditional approval based on Aduhelm’s ability to clear the toxic proteins, called beta-amyloid.”

While we still lack a complete cause and effect model of Alzheimer’s disease, there is no doubt that the etiology is multifaceted and nonlinear. This accounts for the fact that it takes an incredibly long time for Alzheimer’s disease to develop. I mention this because one of the major problems with FDA approval has always been that it insists on utilizing the same framework and methodology of approving drugs designed to treat long-term diseases as it would with short-term diseases.

To the fullest extent of my knowledge (which isn’t much), there is no model that can quantify the relationship between beta-amyloid levels and cognitive function, let alone with time factored in. Just how it takes Alzheimer’s a long time to develop, it may also take treatment an extended period of time to demonstrate improvements. The FDA needs to start utilizing this framework in how it goes about assessing for approval for therapeutics.

While there are numerous roadblocks to providing a viable treatment for Alzheimer’s, the FDA approval of aducanumab marks the first step towards a mechanistic, science-based approach to medicine. Here’s to hoping more will follow suit.

Robert Trent is a graduate student who blogs at Medaphysics.

Image credit: Shutterstock.com

Prev

Let’s talk about vanishing twin syndrome [PODCAST]

July 3, 2021 Kevin 0
…
Next

How I accepted hair loss at 19

July 4, 2021 Kevin 0
…

Tagged as: Medications, Neurology

Post navigation

< Previous Post
Let’s talk about vanishing twin syndrome [PODCAST]
Next Post >
How I accepted hair loss at 19

More by Robert Trent

  • Are we underestimating the danger of prions and prion based diseases?

    Robert Trent
  • Getting a second opinion can save lives. It is time we make Miranda rights for patients.

    Robert Trent
  • What role does the science of complexity play in medicine?

    Robert Trent

Related Posts

  • Take politics out of science and medicine

    Allison Neitzel, MD
  • Considering the recent setbacks of evidence-based medicine

    Kenneth Lin, MD
  • How social media can advance humanism in medicine

    Pooja Lakshmin, MD
  • Is social media a friend or foe of science?

    Michael Joyce, MD
  • The difference between learning medicine and doing medicine

    Steven Zhang, MD
  • KevinMD at the Richmond Academy of Medicine

    Kevin Pho, MD

More in Meds

  • Telemedicine in the opioid crisis: a game-changer threatened by DEA regulations

    Julie Craig, MD
  • The real cause of America’s opioid crisis: Doctors are not to blame

    Richard A. Lawhern, PhD
  • Can personalized medicine live up to its hype in health care?

    Ketan Desai, MD, PhD
  • The effects of the nationwide stimulant shortage on a private psychiatry practice

    Christine Tran-Boynes, DO
  • Why North American medical cannabis can’t compete globally

    Michael Sassano
  • How were we duped and what can we do about the opioid overdose crisis?

    Ronald A. Zent, MD
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • The psychoanalytic hammer: lessons in listening and patient-centered care

      Greg Smith, MD | Conditions
    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
    • Safe sex for seniors: Dispelling myths and embracing safe practices [PODCAST]

      The Podcast by KevinMD | Podcast
    • Overcoming Parkinson’s: a journey of laughter and resilience

      Cynthia Poire Mathews, FNP | Conditions
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • Maximize sleep efficiency with stimulus control

      Pedram Navab, DO | Conditions
    • The Iranian diaspora’s fight for liberty: Overcoming challenges in the largest women’s rights movement of our century

      Montreh Tavakkoli, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • How This Doctor Found Purpose After a Devastating Injury
  • House Lawmakers Squabble Over HHS Budget
  • Infant Formula Crisis Exposed FDA and Industry Failings, Lawmakers Say
  • Building Vaccine Trust Among the General Public
  • Is It Business as Usual for the Drug Industry?

Meeting Coverage

  • Phase III Trials 'Hit a Home Run' in Advanced Endometrial Cancer
  • Cannabis Use Common in Post-Surgery Patients on Opioid Tapering
  • Less Abuse With Extended-Release Oxycodone, Poison Center Data Suggest
  • Novel Strategies Show Winning Potential in Ovarian Cancer
  • Children Do Well With Fewer Opiates After Surgery
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • The psychoanalytic hammer: lessons in listening and patient-centered care

      Greg Smith, MD | Conditions
    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
    • Safe sex for seniors: Dispelling myths and embracing safe practices [PODCAST]

      The Podcast by KevinMD | Podcast
    • Overcoming Parkinson’s: a journey of laughter and resilience

      Cynthia Poire Mathews, FNP | Conditions
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • Maximize sleep efficiency with stimulus control

      Pedram Navab, DO | Conditions
    • The Iranian diaspora’s fight for liberty: Overcoming challenges in the largest women’s rights movement of our century

      Montreh Tavakkoli, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Does the FDA approval of aducanumab mark the return of science-based medicine?
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...